CWBR CohBar, Inc. Stock Quote

CWBR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	6.00%	Shs Outstand	86.06M	Perf Week	-15.30%
Market Cap	29.04M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	3.50%	Shs Float	67.23M	Perf Month	-21.16%
Income	-17.40M	PEG	-	EPS next Q	-0.06	Inst Own	16.30%	Short Float	1.49%	Perf Quarter	-66.61%
Sales	-	P/S	-	EPS this Y	-9.40%	Inst Trans	49.88%	Short Ratio	0.52	Perf Half Y	-72.27%
Book/sh	0.22	P/B	1.42	EPS next Y	8.00%	ROA	-96.60%	Target Price	4.12	Perf Year	-81.88%
Cash/sh	0.16	P/C	1.94	EPS next 5Y	-	ROE	-115.40%	52W Range	0.33 - 2.27	Perf YTD	-10.43%
Dividend	-	P/FCF	-	EPS past 5Y	-22.50%	ROI	-	52W High	-86.19%	Beta	2.44
Dividend %	-	Quick Ratio	6.80	Sales past 5Y	-	Gross Margin	-	52W Low	-5.32%	ATR	0.03
Employees	11	Current Ratio	6.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	30.08	Volatility	8.21% 9.40%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	16.90%	Profit Margin	-	Rel Volume	0.41	Prev Close	0.34
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 15 AMC	Payout	-	Avg Volume	1.93M	Price	0.31
Recom	2.00	SMA20	-17.26%	SMA50	-31.21%	SMA200	-68.61%	Volume	784,761	Change	-6.92%

Mar-15-21

Initiated

Aegis Capital

Buy

Jan-13-22 01:38PM	Tri-Star Advisors Inc. Buys iShares TIPS Bond ETF, iShares Fallen Angels USD Bond ETF, BTC ... GuruFocus.com -5.13%
Jan-03-22 09:00AM	CohBar to Present at H.C. Wainwright BIOCONNECT Conference GlobeNewswire +13.15%
Dec-31-21 11:22AM	7 of the Best Penny Stocks Under $3 for 2022 to Buy Now InvestorPlace
Dec-17-21 09:00AM	CohBar Announces Changes to its Board of Directors and R&D Leadership GlobeNewswire
Nov-29-21 09:00AM	CohBars CEO to Participate in Upcoming BIO Webinar GlobeNewswire
Nov-19-21 09:47AM	7 Penny Stocks With the Potential to 10X in 2022 InvestorPlace
Nov-15-21 04:02PM	CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire -5.32%
Nov-03-21 08:33AM	CohBar, Inc. (NASDAQ:CWBR) may have lost US$647k in value but insiders who invested last year have seen gains of around US$8.6k to date Simply Wall St.
Nov-02-21 01:14AM	Penny Stocks to Buy Using Technical Analysis for November 2021 Investopedia
Nov-01-21 09:00AM	CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021 GlobeNewswire +8.00%
Oct-28-21 02:45PM	Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results Benzinga -37.83%
08:45AM	CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants GlobeNewswire
Oct-27-21 04:01PM	CohBar Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Oct-13-21 09:00AM	CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021 GlobeNewswire
Sep-15-21 09:00AM	CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors GlobeNewswire
Sep-08-21 09:00AM	CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH) GlobeNewswire
Sep-02-21 04:05PM	CohBar to Present at Upcoming Investor Conferences GlobeNewswire
Aug-20-21 09:46AM	5 Penny Stocks Insiders Are Buying Benzinga +9.35%
Aug-16-21 09:00AM	CohBar Appoints Carol Nast to Its Board of Directors GlobeNewswire -15.38%
Aug-12-21 12:50PM	10 Penny Stocks Redditors are Buying in August Insider Monkey -10.49%
Aug-10-21 04:04PM	CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
04:02PM	CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity GlobeNewswire
Aug-04-21 04:05PM	CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021 GlobeNewswire
Jul-14-21 09:00AM	CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity GlobeNewswire -18.12%
Jun-10-21 09:00AM	CohBar to Present at the BIO 2021 Digital Conference GlobeNewswire
May-17-21 04:02PM	CohBar Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
03:15PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
May-03-21 09:00AM	CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021 GlobeNewswire
Apr-27-21 08:30AM	CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director GlobeNewswire -5.80%
Apr-22-21 09:56AM	New Strong Sell Stocks for April 22nd Zacks +6.90%
Apr-21-21 09:00AM	CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity GlobeNewswire +6.42%
Apr-14-21 09:00AM	CohBar to Present at the Mitochondria-Targeted Drug Development Summit GlobeNewswire
Mar-30-21 04:02PM	CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
02:45PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
Mar-29-21 09:00AM	CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity GlobeNewswire
Mar-16-21 04:05PM	CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021 GlobeNewswire
09:00AM	CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases GlobeNewswire
Mar-12-21 09:00AM	CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference GlobeNewswire
Mar-02-21 09:00AM	CohBar to Present at the 33rd Annual ROTH Conference GlobeNewswire
Feb-25-21 09:00AM	CohBar to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -7.14%
Feb-09-21 09:00AM	CohBar to Present at the BIO CEO & Investor Digital Conference GlobeNewswire
Jan-20-21 09:00AM	CohBar to Present at the 3rd Annual Longevity Therapeutics Conference GlobeNewswire +6.38%
Jan-11-21 09:00AM	CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS GlobeNewswire
Dec-09-20 09:00AM	CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model GlobeNewswire
Nov-19-20 09:00AM	CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-16-20 04:01PM	CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +5.50%
03:15PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
Nov-09-20 03:30PM	These 3 Penny Stocks Could Rally Over 100%, Says Roth Capital TipRanks +8.48%
Nov-02-20 09:00AM	CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020 GlobeNewswire
07:35AM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E Zacks
Oct-29-20 09:00AM	CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Oct-27-20 09:00AM	CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event GlobeNewswire
Oct-26-20 09:00AM	CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model GlobeNewswire
Oct-15-20 04:05PM	CohBar to Present at the BIO-Europe Conference GlobeNewswire
Oct-08-20 09:00AM	CohBars CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference GlobeNewswire
Oct-05-20 09:00AM	CohBar to Present at the BIO Investor Forum GlobeNewswire
Sep-29-20 04:05PM	CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference GlobeNewswire
Sep-10-20 04:05PM	CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit GlobeNewswire
Sep-04-20 11:24AM	Insider Buys CohBar's Stock Benzinga +6.00%
Sep-03-20 08:45AM	CohBar to Present at the H.C. Wainwright Annual Global Investment Conference GlobeNewswire -10.71%
Aug-28-20 04:05PM	CohBar Announces Closing of Public Offering of Common Stock and Warrants GlobeNewswire +8.00%
Aug-26-20 08:30AM	CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants GlobeNewswire -32.64%
Aug-25-20 04:55PM	CohBar Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Aug-24-20 09:00AM	CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity GlobeNewswire
Aug-13-20 04:03PM	CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-05-20 09:00AM	CohBar Presents New Antifibrotic Data at the American Thoracic Societys Virtual 2020 Conference GlobeNewswire +8.39%
Jul-30-20 09:00AM	CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 GlobeNewswire
Jul-07-20 09:00AM	CohBar Resumes CB4211 Phase 1b Clinical Trial GlobeNewswire
Jul-06-20 09:00AM	CohBar to Present at Sachs Novel Coronavirus Investment Forum GlobeNewswire +6.00%
Jun-30-20 09:00AM	CohBar Added to Russell 2000® Index and Raises $4.4M in ATM Offering GlobeNewswire
Jun-17-20 09:00AM	CohBar Founder Dr. Nir Barzilais New Book AGE LATER Reveals that Aging Can Be Seen as a Preventable Disease GlobeNewswire
Jun-02-20 09:00AM	CohBar to Hold 2020 Annual Shareholder Meeting and Investor Update June 16, 2020 GlobeNewswire +6.43%
May-27-20 09:00AM	CohBars CEO to Participate on the New Breakthroughs in Aging Biology Panel at the BIO 2020 Digital Conference GlobeNewswire
May-14-20 04:02PM	CohBar Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire -12.50%
May-13-20 09:00AM	CohBars Chief Operating Officer Jon Stern Plans to Step Down from Management Role GlobeNewswire -8.72%
May-05-20 09:00AM	CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides GlobeNewswire +19.40%
May-01-20 11:00AM	CohBars Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine GlobeNewswire +10.98%
Apr-30-20 09:00AM	CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020 GlobeNewswire -6.25%
Apr-19-20 09:21AM	Is CohBar, Inc. (NASDAQ:CWBR) A Volatile Stock? Simply Wall St.
Apr-14-20 08:30AM	CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference GlobeNewswire +5.79%
Mar-30-20 08:45AM	CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity GlobeNewswire -18.37%
Mar-12-20 04:02PM	CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -17.05%
03:00PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
08:30AM	CohBar to Hold Investor Meetings at the ROTH Virtual Conference GlobeNewswire
Mar-02-20 04:30PM	CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020 GlobeNewswire
Jan-28-20 09:00AM	CohBar to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire
Jan-22-20 09:00AM	CohBar Appoints Jordyn Tarazi as Director of Investor Relations GlobeNewswire +9.66%
Jan-08-20 09:00AM	CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis GlobeNewswire
Dec-23-19 08:04PM	Hedge Funds Have Never Been This Bullish On CohBar, Inc. (CWBR) Insider Monkey
Dec-16-19 09:00AM	CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis GlobeNewswire +9.25%
Nov-06-19 04:04PM	CohBar Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire -7.77%
Nov-05-19 09:00AM	CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity GlobeNewswire
Oct-24-19 09:00AM	CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019 GlobeNewswire
Oct-23-19 08:45AM	CohBar Expands Board with Biotech Veteran Misha Petkevich GlobeNewswire +5.96%
Oct-15-19 09:00AM	CohBar to Present at the 2019 BIO Investor Forum GlobeNewswire
Aug-07-19 04:05PM	CohBar Reports Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Jul-31-19 04:05PM	CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019 GlobeNewswire
Jun-10-19 09:00AM	CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions GlobeNewswire +18.29%
Jun-05-19 09:00AM	CohBar to Hold 2019 Annual Shareholder Meeting and Investor Update June 18, 2019 GlobeNewswire -14.36%
May-29-19 09:00AM	CohBar to Present Data on Novel Analogs of a Mitochondrially Encoded Peptide with Beneficial Effects in an Animal Model of Type 2 Diabetes at the American Diabetes Association 79th Scientific Sessions GlobeNewswire

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Petkevich Misha	Director	Oct 28	Buy	0.58	167,000	96,175	407,609	Nov 01 09:15 AM
Sarret Joseph J.	Chief Executive Officer	Aug 18	Buy	1.12	20,000	22,400	20,000	Aug 19 09:00 AM
Cundy Kenneth C	Chief Scientific Officer	Aug 11	Option Exercise	0.73	10,000	7,300	20,000	Aug 13 04:02 PM
Cundy Kenneth C	Chief Scientific Officer	Aug 11	Sale	2.01	10,000	20,100	10,000	Aug 13 04:02 PM
Cundy Kenneth C	Chief Scientific Officer	Feb 16	Option Exercise	0.73	10,000	7,300	20,000	Feb 18 04:30 PM
Cundy Kenneth C	Chief Scientific Officer	Feb 16	Sale	1.90	10,000	19,000	10,000	Feb 18 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience